首页> 美国卫生研究院文献>Oncotarget >Correlation of thyroid stimulating hormone receptor mRNA expression levels in peripheral blood with undesirable clinicopathological features in papillary thyroid carcinoma patients
【2h】

Correlation of thyroid stimulating hormone receptor mRNA expression levels in peripheral blood with undesirable clinicopathological features in papillary thyroid carcinoma patients

机译:甲状腺乳头状癌患者外周血甲状腺刺激激素受体mRNA表达水平与不良临床病理特征的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To determine the extent to which thyroid stimulating hormone receptor (TSHR) mRNA in peripheral blood (PB) has diagnostic value for papillary thyroid carcinoma (PTC). We obtained pre- and postoperative PB samples from 104 thyroid disease patients and collected 11 healthy volunteers’ PB samples twice apiece at different times. We used reverse transcription polymerase chain reaction (RT-PCR) to quantify TSHR mRNA expression levels in the samples. T-test and chi-square test were used to compare quantitative data and rates. The mean preoperative PB TSHR mRNA expression level of the PTC patients was significantly higher than that of the healthy volunteers. However, on the postoperative day 1, PB TSHR mRNA level of PTC patients significantly decreased but not for healthy controls. Preoperative PB TSHR mRNA expression levels were significantly associated with patient age, capsular invasion status, lymph node metastasis status, and BRAFV600E mutation status (P < 0.05) but not gender, tumor size, number of cancer foci, or Hashimoto thyroiditis status. Preoperative assessment of the PB TSHR mRNA expression level combined with ultrasonography of the thyroid had better accuracy in the diagnosis of PTC than either method alone did. Moreover, TSHR mRNA expression significantly affected recurrence of PTC patients. Our findings suggest that PB TSHR mRNA expression level is a promising novel biomarker for the early detection, diagnosis, and treatment of PTC. It may serve as a noninvasive means of PTC detection and a prognostic biomarker of residual tumor and help guide further treatment.
机译:为了确定外周血(PB)中的甲状腺刺激激素受体(TSHR)mRNA对乳头状甲状腺癌(PTC)有诊断价值的程度。我们从104位甲状腺疾病患者的术前和术后获得了PB样本,并在不同时间两次收集了11名健康志愿者的PB样本。我们使用逆转录聚合酶链反应(RT-PCR)来量化样品中TSHR mRNA的表达水平。使用T检验和卡方检验比较定量数据和比率。 PTC患者的术前PB TSHR mRNA平均表达水平显着高于健康志愿者。但是,在术后第1天,PTC患者的PB TSHR mRNA水平显着下降,但健康对照者并未下降。术前PB TSHR mRNA表达水平与患者年龄,荚膜浸润状态,淋巴结转移状态和BRAF V600E 突变状态显着相关(P <0.05),而与性别,肿瘤大小,癌灶数目无关或桥本甲状腺炎状态。术前评估PB TSHR mRNA表达水平并结合甲状腺超声检查对PTC的诊断比单独使用任何一种方法具有更好的准确性。此外,TSHR mRNA表达显着影响PTC患者的复发。我们的发现表明,PB TSHR mRNA表达水平对于PTC的早期检测,诊断和治疗是一种有前途的新型生物标记。它可以作为PTC检测的非侵入性手段和残留肿瘤的预后生物标志物,并有助于指导进一步的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号